By Editor • August 30, 2026 • 1 min read
The FDA has recently approved rusfertide, a new drug designed to combat polycythemia vera, a rare blood cancer that leads to excessive red blood cell production.
Developed by Protagonist Therapeutics and marketed by Takeda as Mimrylo, the treatment is administered through weekly injections.
Source: www.statnews.com
#FDA #Mimrylo #polycythemia vera #Protagonist Therapeutics #Takeda
By Editor • August 30, 2026 • 1 min read
Alnylam Pharmaceuticals defends its heart disease drugs after AstraZeneca's failed trial raises concerns about the efficacy of silencers.
Read moreBy Editor • August 30, 2026 • 1 min read
Experts now say that a weekend lie-in of about 90 minutes can be beneficial for heart health, challenging previous warnings against oversleeping.
Read moreBy Editor • August 30, 2026 • 1 min read
Diarrhea discussions rise in the US, linked to a cyclosporiasis outbreak; most cases are self-limiting and manageable with hydration.
Read more
